Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.
10.3350/cmh.2013.19.3.273
- Author:
Jeong Han KIM
1
;
Soon Young KO
;
Won Hyeok CHOE
;
So Young KWON
;
Chang Hong LEE
Author Information
1. Digestive Disease Center, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea. 93haan@hanmail.net
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Chronic hepatitis B;
Lamivudine;
Adefovir;
Resistance;
Hepatocellular carcinoma
- MeSH:
Adenine/*analogs & derivatives/therapeutic use;
Adult;
Antiviral Agents/*therapeutic use;
Carcinoma, Hepatocellular/*diagnosis/epidemiology/etiology;
DNA, Viral/analysis;
Drug Administration Schedule;
Drug Resistance, Viral;
Drug Therapy, Combination;
Genotype;
Hepatitis B virus/genetics;
Hepatitis B, Chronic/*drug therapy/virology;
Humans;
Incidence;
Lamivudine/*therapeutic use;
Liver Cirrhosis/diagnosis/epidemiology/etiology;
Liver Neoplasms/*diagnosis/epidemiology/etiology;
Middle Aged;
Organophosphonates/*therapeutic use;
Retrospective Studies;
Treatment Outcome
- From:Clinical and Molecular Hepatology
2013;19(3):273-279
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB). The aim of this study was to determine the efficacy of this combination therapy in hepatocellular carcinoma (HCC) patients. METHODS: The medical records of CHB patients who developed LAM resistance and were treated with LAM plus ADV combination therapy for more than 6 months were reviewed. Their virological response (VR; undetectable HBV DNA) and biochemical response (BR; alanine aminotransferase normalization) were evaluated, and the findings of HCC and non-HCC patients were compared. RESULTS: The data from 104 patients (19 with HCC and 85 without HCC) were analyzed. The VR rates did not differ significantly between the HCC and non-HCC groups: 33.3% vs. 55.6% at 12 months (P=0.119), 58.3% vs. 67.2% at 24 months (P=0.742), 50% vs. 69.8% at 36 months (P=0.280), and 66.7% vs. 71.0% at 48 months (P=1.000). The BR rates also did not differ significantly between the groups: 55.6% vs. 84.0% at 12 months (P=0.021), 58.3% vs. 83.8% at 24 months (P=0.057), 70.0% vs. 77.8% at 36 months (P=0.687), and 66.7% vs. 80.6% at 48 months (P=0.591). CONCLUSIONS: The efficacy of LAM plus ADV combination therapy is comparable in HCC and non-HCC patients.
